← Valneva SE (VLS) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
Valneva SE (VLS)
Biotechnology · market cap —
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
None scheduled
Pipeline
18
programs
Upcoming events
0
next 90d+
Dossier
Not yet
generate it
The catalyst path
No upcoming catalysts in our calendar.
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| VLA1701 | Phase 2 | Enterotoxigenic Escherichia Coli Infection |
| Japanese Encephalitis purified inactivated vaccine (IC51) | Phase 3 | Japanese Encephalitis |
| VLA1553 | Phase 3 | Chikungunya Virus Infection |
| Biological Vaccine VLA1553 | Phase 3 | Chikungunya Virus Infection |
| IC51 | Phase 3 | Japanese Encephalitis |
| VLA1553 full dose | Phase 2 | Chikungunya Virus Infection |
| JE-VAX | Phase 3 | Japanese Encephalitis |
| IC43 | Phase 3 | Pseudomonas Aeruginosa Infection |
| IC51 has given in the parent study IC51-322 | Phase 3 | Japanese Encephalitis |
| Japanese Encephalitis purified inactivated vaccine | Phase 3 | Japanese Encephalitis |
| IC51 Japanese Encephalitis | Phase 3 | Encephalitis |
| VLA84 | Phase 2 | Clostridium Difficile |
| IC41 | Phase 2 | Chronic Hepatitis C |
| AZD1222 | Phase 3 | SARS-CoV-2 Virus Infection |
| IXIARO | Phase 3 | Japanese Encephalitis |
| VLA2001 | Phase 3 | SARS-CoV-2 Virus Infection |
| VLA15 | Phase 3 | Lyme Borreliosis |
| Active | Phase 3 | Chikungunya |
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for VLS (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 18 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.